托伐普坦结构式
|
常用名 | 托伐普坦 | 英文名 | Tolvaptan |
---|---|---|---|---|
CAS号 | 150683-30-0 | 分子量 | 448.941 | |
密度 | 1.3±0.1 g/cm3 | 沸点 | 594.4±50.0 °C at 760 mmHg | |
分子式 | C26H25ClN2O3 | 熔点 | 219-222°C | |
MSDS | 中文版 美版 | 闪点 | 313.3±30.1 °C |
托伐普坦用途Tolvaptan是精氨酸加压素受体2拮抗剂,能抑制AVP-诱导的血小板聚集,IC50为1.28μM。 |
中文名 | 托伐普坦 |
---|---|
英文名 | N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide |
中文别名 | 托伐坦 | N-[4-[(5R)-7-氯-5-羟基-2,3,4,5-四氢-1-苯并氮杂卓-1-甲酰基]-3-甲基苯基]-2-甲基苯甲酰胺 |
英文别名 | 更多 |
描述 | Tolvaptan是精氨酸加压素受体2拮抗剂,能抑制AVP-诱导的血小板聚集,IC50为1.28μM。 |
---|---|
相关类别 | |
参考文献 |
[2]. Inomata T.Tolvaptan (vasopressin receptor antagonist).Nihon Rinsho. 2011 Nov;69 Suppl 9:408-11. |
密度 | 1.3±0.1 g/cm3 |
---|---|
沸点 | 594.4±50.0 °C at 760 mmHg |
熔点 | 219-222°C |
分子式 | C26H25ClN2O3 |
分子量 | 448.941 |
闪点 | 313.3±30.1 °C |
精确质量 | 448.155365 |
PSA | 69.64000 |
LogP | 4.09 |
外观性状 | white to tan |
蒸汽压 | 0.0±1.8 mmHg at 25°C |
折射率 | 1.664 |
储存条件 | Refrigerator |
水溶解性 | DMSO: ≥15mg/mL |
危险品运输编码 | NONH for all modes of transport |
---|
托伐普坦上游产品 9 | |
---|---|
托伐普坦下游产品 1 | |
Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial).
Am. J. Cardiol. 114(11) , 1713-21, (2014) We investigated the clinical profiles associated with serum uric acid (sUA) levels in a large cohort of patients hospitalized for worsening chronic heart failure with ejection fraction (EF) ≤40%, with... |
|
Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.
J. Am. Soc. Nephrol. 26(1) , 39-47, (2015) Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of ESRD. A central defect associated with ADPKD pathology is elevated levels of 3', 5'-cyclic AMP (cAMP). Compounds such as tolv... |
|
Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
Circ. Heart Fail. 6(1) , 47-52, (2013) Arginine vasopressin (AVP) levels are elevated in proportion to heart failure severity and are associated with higher cardiovascular mortality in ambulatory patients. However, the relationship between... |
(±)-4'-[(7-chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-o-tolu-m-toluidide |
Tolvaptan |
UNII-21G72T1950 |
olvaptan |
N-{4-[(7-Chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl}-2-methylbenzamide |
Benzamide, N-[4-[(7-chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methyl- |
Samsca |
benzazepine derivative,32 |
N-[4-(9-chloro-6-hydroxy-2-azabicyclo[5.4.0]undeca-8,10,12-triene-2-carbonyl)-3-methyl-phenyl]-2-methyl-benzamide |